Li Yinglei, Xi Lingyun, Sun Haichuan, Yu Feifei, Liang Qing, Qie Tao, Dai Bing
Department of Emergency Medicine, Baoding NO.1 Central Hospital, Baoding, People's Republic of China.
Department of Laboratory and Pathology, The Hospital of 82nd Group Army PLA, Baoding, People's Republic of China.
Int J Gen Med. 2024 Nov 26;17:5511-5521. doi: 10.2147/IJGM.S489482. eCollection 2024.
The objective of this study is to examine the correlation between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV) with the outcome following 3 months of thrombolysis in individuals diagnosed with acute ischemic stroke.
A retrospective analysis was conducted on a cohort of 762 patients who received intravenous thrombolysis between January 2019 and December 2022. The values of NLR, PLR, LMR, SII, SIRI and PIV were calculated based on relevant blood indices obtained upon admission. Logistic regression analysis using R software was employed to examine the correlation between SIRI, SII, PIV, and poor prognosis following 3 months of thrombolysis, with their distribution analyzed across the study population and various outcomes. Receiver operating characteristic (ROC) curves were utilized to analyze and evaluate their predictive efficacy for adverse outcomes.
The unfavorable prognosis group exhibited significant differences from the favorable prognosis group in various hematological markers, including PLR, NLR, LMR, SII, SIRI, and PIV, as indicated by ROC values of 0.613 (95% confidence interval (CI), 0.564-0.661), 0.707 (95% CI, 0.663-0.751), 0.614 (95% CI, 0.567-0.662), 0.715 (95% CI, 672-0.758), 0.631 (95% CI, 0.584-0.679), and 0.569 (95% CI, 0.520-0.619) respectively. (4) Conclusions: PLR, NLR, LMR, SII, SIRI, and PIV demonstrated associations with adverse outcomes at the 3-month mark in patients who underwent intravenous thrombolysis, with NLR (ROC is 0.707) and SII (ROC is 0.715) showing the most pronounced significance and PIV (ROC is 0.569) exhibiting the least significance.
本研究旨在探讨中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、淋巴细胞与单核细胞比值（LMR）、全身免疫炎症指数（SII）、全身炎症反应指数（SIRI）和全免疫炎症值（PIV）与急性缺血性中风患者溶栓3个月后的预后之间的相关性。
对2019年1月至2022年12月期间接受静脉溶栓治疗的762例患者进行回顾性分析。根据入院时获得的相关血液指标计算NLR、PLR、LMR、SII、SIRI和PIV的值。使用R软件进行逻辑回归分析，以检验SIRI、SII、PIV与溶栓3个月后不良预后之间的相关性，并分析它们在研究人群和各种结局中的分布情况。采用受试者工作特征（ROC）曲线分析和评估它们对不良结局的预测效能。
不良预后组与良好预后组在包括PLR、NLR、LMR、SII、SIRI和PIV在内的各种血液学指标上存在显著差异，其ROC值分别为0.613（95%置信区间（CI），0.564 - 0.661）、0.707（95%CI，0.663 - 0.751）、0.614（95%CI，0.567 - 0.662）、0.715（95%CI，672 - 0.758）、0.631（95%CI，0.584 - 0.679）和0.569（95%CI，0.520 - 0.619）。（4）结论：PLR、NLR、LMR、SII、SIRI和PIV与接受静脉溶栓治疗患者3个月时的不良结局相关，其中NLR（ROC为0.707）和SII（ROC为0.715）显示出最显著的意义，而PIV（ROC为0.569）显示出的意义最小。
